Dupilumab
This article should be taken with reservations as it has not been validated by a specialist. If you have knowledge on the subject, use reliable sources and references to confirm its quality. Once the article has been improved, remove this template.
Dupixent. Eczema medication. The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an injection for the treatment of adults with moderate to severe eczema (atopic dermatitis).
Patients receiving concomitant oral corticosteroids may reduce their steroid dose once there is clinical improvement with dupilumab Steroid reductions should be made gradually.
Dupilumab is indicated for long-term treatment. Discontinuation of treatment should be considered in patients who have not shown response after 24 weeks of treatment for CRScPN. Some patients with initial partial response may subsequently improve with continued treatment after 24 weeks.
Dupixent price colombia
This drug is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are encouraged to report suspected adverse reactions. See section 4.8 for information on how to report them.
Dupixent is indicated as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe CRScPN for whom systemic corticosteroid therapy and/or surgery does not provide adequate disease control.
Dupilumab can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved only for problem areas, such as the face, neck, intertriginous and genital areas.
Patients receiving concomitant oral corticosteroids may reduce their steroid dose once there is clinical improvement with dupilumab (see section 5.1). Steroid reductions should be made gradually (see section 4.4).
Dupilumab side effects
This drug is subject to additional monitoring, which will expedite the detection of new safety information. You can contribute by reporting any adverse effects you may have. The final part of section 4 includes information on how to report these side effects.
Dupilumab is a monoclonal antibody (a specialized type of protein) that blocks the action of proteins called IL-4 and IL-13. Both play a key role in the onset of the signs and symptoms of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRScPN).
Dupixent is also used, along with other medications, for the maintenance treatment of CRScPN in adults whose disease is not controlled with their current CRScPN medication. Dupixent may also reduce the need for surgery and the need for the use of systemic corticosteroids.
Dupixent helps prevent severe asthma attacks (exacerbations) and may improve your breathing ability. Dupixent may also help reduce the amount of another group of medicines you need to control your asthma, called oral corticosteroids, while preventing severe asthma attacks and improving your breathing ability.
Dupixent mercadolibre price
This drug is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are invited to report suspected adverse reactions. See section 4.8 for information on how to report them.
Dupixent is indicated as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe CRPScPN for whom systemic corticosteroid therapy and/or surgery does not provide adequate disease control.
Dupilumab can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved only for problem areas, such as the face, neck, intertriginous and genital areas.
Patients receiving concomitant oral corticosteroids may reduce their steroid dose once there is clinical improvement with dupilumab (see section 5.1). Steroid reductions should be made gradually (see section 4.4).